TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
KR950000167A
(ko)
*
|
1993-06-24 |
1995-01-03 |
다께다 구니오 |
항-엔도테린 물질의 서방 제제
|
US6087324A
(en)
*
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
DE4342091A1
(de)
*
|
1993-12-09 |
1995-06-14 |
Asta Medica Ag |
Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
|
WO1996022786A1
(fr)
*
|
1995-01-23 |
1996-08-01 |
Takeda Chemical Industries, Ltd. |
Preparation a diffusion prolongee et son emploi
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
TW448055B
(en)
*
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
US6143037A
(en)
*
|
1996-06-12 |
2000-11-07 |
The Regents Of The University Of Michigan |
Compositions and methods for coating medical devices
|
US5932547A
(en)
*
|
1996-07-03 |
1999-08-03 |
Alza Corporation |
Non-aqueous polar aprotic peptide formulations
|
US5916582A
(en)
*
|
1996-07-03 |
1999-06-29 |
Alza Corporation |
Aqueous formulations of peptides
|
US5981489A
(en)
*
|
1996-07-18 |
1999-11-09 |
Alza Corporation |
Non-aqueous protic peptide formulations
|
ATE272394T1
(de)
*
|
1996-10-31 |
2004-08-15 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter freisetzung
|
US5968895A
(en)
*
|
1996-12-11 |
1999-10-19 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6126919A
(en)
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
US6030975A
(en)
*
|
1997-03-14 |
2000-02-29 |
Basf Aktiengesellschaft |
Carboxylic acid derivatives, their preparation and use in treating cancer
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
ES2234325T3
(es)
*
|
1998-12-15 |
2005-06-16 |
Takeda Pharmaceutical Company Limited |
Procedimiento para producir poliesteres biodegradables.
|
WO2000048573A1
(fr)
*
|
1999-02-19 |
2000-08-24 |
Bioserv Ag |
Materiaux composites biodegradables pour la fabrication de microcapsules
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
AU2001264264A1
(en)
*
|
2000-06-14 |
2001-12-24 |
Takeda Chemical Industries Ltd. |
Sustained release compositions
|
AU2001269439A1
(en)
|
2000-07-05 |
2002-01-14 |
Takeda Chemical Industries Ltd. |
Medicinal preparations for treating sex hormone-dependent diseases
|
AU2001276733A1
(en)
|
2000-08-07 |
2002-02-18 |
Takeda Chemical Industries Ltd. |
Lactic acid polymer and process for producing the same
|
EP1346722B1
(fr)
|
2000-12-01 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Procede de production d'une preparation contenant une substance bioactive
|
CA2435415A1
(fr)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Microparticules de polymere biodegradable encapsulant une substance biologiquement active et formulations pharmaceutiques a liberation prolongee contenant lesdites particules
|
WO2002058671A1
(fr)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Microparticules pharmaceutiques exemptes d"eclatement
|
WO2003000156A1
(fr)
|
2001-06-22 |
2003-01-03 |
Southern Biosystems, Inc. |
Implants coaxiaux a liberation prolongee d'ordre 0
|
TWI225416B
(en)
|
2001-06-29 |
2004-12-21 |
Takeda Chemical Industries Ltd |
Sustained-release composition and process for producing the same
|
JP2005510521A
(ja)
|
2001-11-12 |
2005-04-21 |
アルカーメス コントロールド セラピューティクス,インコーポレイテッド |
生体適合性ポリマーブレンドおよびその使用
|
CA2466659A1
(fr)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Agents anticancer
|
EP1476178A4
(fr)
*
|
2002-02-14 |
2009-08-26 |
Bayer Pharmaceuticals Corp |
Strategies de formulation dans la stabilisation de peptides dans des solvants organiques et a l'etat seche
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006130217A2
(fr)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Esters de phosphate de phosphonates de nucleosides substitues
|
EP1866319B1
(fr)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Nucleosides phosphono-pent-2-en-1-yle et analogues
|
US7342048B2
(en)
*
|
2005-04-28 |
2008-03-11 |
Nipro Corporation |
Bioabsorbable pharmaceutical formulation
|
WO2007073398A2
(fr)
|
2005-05-23 |
2007-06-28 |
Natural Alternatives International |
Compositions et procedes pour la liberation prolongee de beta-alanine
|
CN101258163B
(zh)
*
|
2005-06-30 |
2013-08-21 |
益普生制药股份有限公司 |
Glp-1药物组合物
|
US20070106271A1
(en)
*
|
2005-11-09 |
2007-05-10 |
Searete Llc, A Limited Liability Corporation |
Remote control of substance delivery system
|
EP1981525B1
(fr)
|
2005-12-30 |
2015-01-21 |
Zensun (Shanghai) Science and Technology Limited |
Liberation etendue de neureguline destinee a ameliorer la fonction cardiaque
|
PL2383271T3
(pl)
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
CN101404981A
(zh)
*
|
2006-03-13 |
2009-04-08 |
恩希赛弗制药公司 |
治疗舒张性心力衰竭的方法和组合物
|
MX2008011844A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Formulaciones de sitaxsentano de sodio.
|
US8323676B2
(en)
*
|
2008-06-30 |
2012-12-04 |
Abbott Cardiovascular Systems Inc. |
Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
|
US20090258028A1
(en)
*
|
2006-06-05 |
2009-10-15 |
Abbott Cardiovascular Systems Inc. |
Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
US8017237B2
(en)
|
2006-06-23 |
2011-09-13 |
Abbott Cardiovascular Systems, Inc. |
Nanoshells on polymers
|
NZ574524A
(en)
|
2006-08-09 |
2011-07-29 |
Intarcia Therapeutics Inc |
Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
|
WO2008036379A2
(fr)
|
2006-09-21 |
2008-03-27 |
Activx Biosciences, Inc. |
Inhibiteurs de serine hydrolase
|
JP2010507585A
(ja)
|
2006-10-19 |
2010-03-11 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
置換インドール
|
WO2008057604A2
(fr)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Agents thérapeutiques contenant de petites molécules, synthèses d'analogues et de dérivés et leurs procédés d'utilisation
|
EP2098507B1
(fr)
|
2006-11-30 |
2014-11-12 |
Takeda Pharmaceutical Company Limited |
Composé d'amine cyclique comme modulateur du récépteur de l'androgène
|
TWI481424B
(zh)
|
2006-12-18 |
2015-04-21 |
Takeda Pharmaceutical |
緩釋性組成物及其製法
|
WO2008106167A1
(fr)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
|
AU2008219622A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
US20080220104A1
(en)
*
|
2007-03-08 |
2008-09-11 |
Cappello John V |
Compositions for producing satiety
|
AU2008251773A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
US8673859B2
(en)
|
2007-03-20 |
2014-03-18 |
New York University |
GM-CSF cosmeceutical compositions and methods of use thereof
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
JP2010533205A
(ja)
*
|
2007-07-12 |
2010-10-21 |
トラガラ ファーマシューティカルズ,インク. |
癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
|
ITSA20070024A1
(it)
*
|
2007-07-27 |
2009-01-28 |
Univ Degli Studi Salerno |
Processo continuo per la produzione di microsfere mediante liquidi espansi.
|
EP2203458B1
(fr)
*
|
2007-09-11 |
2011-11-02 |
Kyorin Pharmaceutical Co., Ltd. |
Cyanoaminoquinolones en tant qu'inhibiteurs de gsk-3
|
CA2699152C
(fr)
|
2007-09-12 |
2015-11-24 |
Activx Biosciences, Inc. |
Aminoquinolones spirocycliques utilisees en tant qu'inhibiteurs de gsk-3
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
CA2726861C
(fr)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
|
MX2010010172A
(es)
|
2008-03-17 |
2010-11-25 |
Ambit Biosciences Corp |
Derivados de quinazolina como moduladores de quinasa raf y metodos de uso de los mismos.
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
CN102083466A
(zh)
*
|
2008-05-20 |
2011-06-01 |
科莱尼斯医疗公司 |
用于组合疗法的烟酸和nsaid
|
US8765162B2
(en)
*
|
2008-06-30 |
2014-07-01 |
Abbott Cardiovascular Systems Inc. |
Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
BRPI0918904B8
(pt)
*
|
2008-09-04 |
2021-05-25 |
Amylin Pharmaceuticals Inc |
formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
|
CA2748389A1
(fr)
|
2008-12-31 |
2010-07-08 |
Scynexis, Inc. |
Derives de cyclosporine a
|
WO2010088450A2
(fr)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Procédés de traitement de maladies associées à la modulation de serca
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
MX2011008995A
(es)
|
2009-02-27 |
2011-09-15 |
Ambit Biosciences Corp |
Derivados de quinazolina de modulacion de cinasa jak y metodos para usar los mismos.
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
JP5502889B2
(ja)
*
|
2009-03-11 |
2014-05-28 |
杏林製薬株式会社 |
gsk−3阻害剤としての7−シクロアルキルアミノキノロン
|
MX2011010105A
(es)
|
2009-03-27 |
2012-01-12 |
Pathway Therapeutics Inc |
Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
|
WO2010110686A1
(fr)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation en thérapie anticancéreuse
|
DK2502921T3
(en)
|
2009-04-22 |
2015-08-10 |
Axikin Pharmaceuticals Inc |
Aryl sulfonamide CCR3 antagonists
|
DK2749554T3
(en)
|
2009-04-22 |
2018-04-03 |
Sma Therapeutics Inc |
2,5-disubstituted arylsulfonamide CCR3 antagonists
|
CN102459178A
(zh)
|
2009-04-22 |
2012-05-16 |
埃克希金医药品有限公司 |
2,5-二取代的芳基磺酰胺ccr3拮抗剂
|
US8911766B2
(en)
*
|
2009-06-26 |
2014-12-16 |
Abbott Cardiovascular Systems Inc. |
Drug delivery compositions including nanoshells for triggered drug release
|
WO2011003870A2
(fr)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Corticostéroïdes mini-pegylés, compositions les comprenant et procédés pour les préparer et les utiliser
|
AR080945A1
(es)
|
2009-07-07 |
2012-05-23 |
Pathway Therapeutics Inc |
Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
|
HUE035519T2
(en)
|
2009-07-08 |
2018-05-02 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical composition
|
EP2467144A1
(fr)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Association d'inhibiteurs du protéasome et de médicaments anti-hépatite dans le traitement de l'hépatite
|
CA2769652A1
(fr)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la serine protease macrocyclique utiles contre les infections virales, en particulier le virus de l?hepatite c
|
US20130035326A1
(en)
|
2009-08-19 |
2013-02-07 |
Ambit Biosciences Corporation |
Biaryl compounds and methods of use thereof
|
WO2011037623A1
(fr)
|
2009-09-28 |
2011-03-31 |
Intarcia Therapeutics, Inc. |
Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
|
TW201120037A
(en)
*
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(fr)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Imidazo[2,1-b][1,3]benzothiazoles enrichis en isotopes ou fluores
|
WO2011064769A1
(fr)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Procédés et compositions pharmaceutiques pour le traitement des bouffées de chaleur
|
WO2011069002A1
(fr)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Composés d'organosélénium et leurs utilisations
|
AU2010330862B2
(en)
|
2009-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
EP2519538A1
(fr)
|
2009-12-30 |
2012-11-07 |
Scynexis, Inc. |
Analogues de cyclosporine
|
WO2011089166A1
(fr)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Inhibiteurs du protéasome à base de semicarbazone pour traiter une infection par le vih et une infection par une hépatite
|
WO2011094890A1
(fr)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
|
WO2011097525A1
(fr)
|
2010-02-05 |
2011-08-11 |
Tragara Pharmaceuticals, Inc. |
Formes à l'état solide d'inhibiteurs macrocycliques de kinases
|
SI3202461T1
(sl)
|
2010-02-11 |
2019-05-31 |
Celgene Corporation |
Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
|
DK2542542T3
(en)
|
2010-03-02 |
2015-07-20 |
Axikin Pharmaceuticals Inc |
ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS
|
WO2011112689A2
(fr)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Sels d'indazolylpyrrolotriazine
|
WO2011116161A2
(fr)
|
2010-03-17 |
2011-09-22 |
Axikin Pharmaceuticals Inc. |
Antagonistes du ccr3 de type arylsulfonamide
|
WO2011150201A2
(fr)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Composés azolylamide et leurs procédés d'utilisation
|
US9296722B2
(en)
|
2010-05-27 |
2016-03-29 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
AU2011261501B2
(en)
|
2010-06-01 |
2016-01-21 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
|
CN104926722A
(zh)
|
2010-06-01 |
2015-09-23 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
NZ604018A
(en)
|
2010-06-07 |
2015-02-27 |
Novomedix Llc |
Furanyl compounds and the use thereof
|
US9295663B2
(en)
|
2010-07-14 |
2016-03-29 |
Abbott Cardiovascular Systems Inc. |
Drug coated balloon with in-situ formed drug containing microspheres
|
US20140200270A1
(en)
|
2013-01-11 |
2014-07-17 |
Summa Health System |
Vitamins c and k for treating polycystic diseases
|
CA2805745C
(fr)
|
2010-07-19 |
2019-01-15 |
Summa Health System |
Vitamine c et vitamine k sans chrome, et leurs compositions dans le traitement d'une pathologie ou d'une maladie dans laquelle intervient le facteur nf-kb
|
US8633207B2
(en)
|
2010-09-01 |
2014-01-21 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
WO2012030924A1
(fr)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Composés d'azolopyridine et d'azolopyrimidine et méthodes d'utilisation associées
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
WO2012030918A1
(fr)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Composés de modulation du récepteur a3 de l'adénosine et leurs méthodes d'utilisation
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
JP5933554B2
(ja)
|
2010-09-01 |
2016-06-15 |
アムビト ビオスシエンセス コルポラチオン |
光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
|
AU2011296046B2
(en)
|
2010-09-01 |
2015-05-14 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
EP2663553B1
(fr)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Composés quinoléine et isoquinoléine en tant que modulateurs de jak
|
WO2012044641A1
(fr)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinylbenzimidazolsulfonamides et leur utilisation en thérapie anticancéreuse
|
AU2011313906B2
(en)
|
2010-10-11 |
2015-08-13 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide CCR3 antagonists
|
EP2637669A4
(fr)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Composés hétérocycliques et utilisations de ceux-ci
|
JP2014500275A
(ja)
|
2010-12-06 |
2014-01-09 |
フォリカ,インコーポレイテッド |
禿頭症を治療するため、および毛髪の成長を促進するための方法
|
WO2012080050A1
(fr)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Formes solides d'un composé de phénoxybenzènesulfonyle
|
KR101411349B1
(ko)
*
|
2010-12-24 |
2014-06-25 |
주식회사 삼양바이오팜 |
생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
|
CN103648499B
(zh)
|
2011-01-10 |
2017-02-15 |
无限药品股份有限公司 |
用于制备异喹啉酮的方法及异喹啉酮的固体形式
|
CA2825152A1
(fr)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Compositions pharmaceutiques d'analogues de cytidine et leurs methodes d'utilisation
|
WO2012109398A1
(fr)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
EA201391319A1
(ru)
|
2011-03-11 |
2014-03-31 |
Селджин Корпорейшн |
Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
|
RU2608742C2
(ru)
|
2011-03-28 |
2017-01-23 |
ЭмИАй ФАРМА, ИНК. |
(альфа-замещенные аралкиламино- и гетероарилалкиламино)пиримидинил- и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний
|
WO2012135166A1
(fr)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(arylamino et hétérocyclylamino à cycle condensé)pyrimidinyl- et 1,3,5-triazinylbenzimidazoles, compositions pharmaceutiques de ceux-ci et leur utilisation dans le traitement de maladies prolifératives
|
SG193984A1
(en)
|
2011-03-28 |
2013-11-29 |
Mei Pharma Inc |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2838991A1
(fr)
|
2011-06-23 |
2012-12-27 |
Map Pharmaceuticals, Inc. |
Nouveaux analogues de fluoro-ergoline
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
AU2012284091B2
(en)
|
2011-07-19 |
2015-11-12 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
WO2013039855A1
(fr)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Composés et compositions pharmaceutiques pour le traitement d'infections virales
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
WO2013056046A1
(fr)
|
2011-10-14 |
2013-04-18 |
Idenix Pharmaceuticals, Inc. |
Phosphates 3',5'-cycliques substitués de composés nucléotidiques purines et compositions pharmaceutiques pour le traitement d'infections virales
|
KR102066297B1
(ko)
|
2011-10-14 |
2020-01-14 |
암비트 바이오사이언시즈 코포레이션 |
헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
|
EP2793580A4
(fr)
|
2011-12-19 |
2015-05-20 |
Map Pharmaceuticals Inc |
Nouveaux dérivés d'iso-ergoline
|
WO2013095708A1
(fr)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Nouveaux composés neuromodulateurs
|
US9611253B2
(en)
|
2012-02-29 |
2017-04-04 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
NZ628084A
(en)
|
2012-03-16 |
2016-09-30 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
WO2013177195A1
(fr)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
|
WO2013177188A1
(fr)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
JP6246712B2
(ja)
|
2012-07-12 |
2017-12-13 |
武田薬品工業株式会社 |
マイクロカプセル粉末の製造方法
|
EP3524598B1
(fr)
|
2012-08-09 |
2021-07-07 |
Celgene Corporation |
UNE FORME SOLIDE D'HYDROCHLORURE DE 
(S)-3-(4-((4-MORPHOLINOMÉTHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPÉRIDINE-2,6-DIONE
|
PL2882441T3
(pl)
|
2012-08-09 |
2020-09-21 |
Celgene Corporation |
Leczenie chorób immunologicznych i zapalnych
|
EP2890370B1
(fr)
|
2012-08-31 |
2019-10-09 |
The Regents of the University of California |
Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
|
BR112015004959A2
(pt)
|
2012-09-07 |
2017-07-04 |
Axikin Pharmaceuticals Inc |
composto isotopicamente enriquecido, composição farmacêutica, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença, distúrbio ou condição mediada por ccr3, relacionada a eosinófilos, relacionada a basófilos, relacionada a mastócitos ou relacionada a mastócitos em um sujeito, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença inflamatória em um sujeito e método para modular a atividade de ccr3.
|
WO2014055647A1
(fr)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl et sulfonyl benzimidazolyl) pyrimidines et triazines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter les maladies prolifératives
|
US10513534B2
(en)
|
2012-10-08 |
2019-12-24 |
Idenix Pharmaceuticals Llc |
2′-chloro nucleoside analogs for HCV infection
|
EP2909223B1
(fr)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Composés dinucléotides contre une infection par le vhc
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
HUE040126T2
(hu)
|
2012-11-01 |
2019-02-28 |
Infinity Pharmaceuticals Inc |
Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
|
EP2916830A2
(fr)
|
2012-11-08 |
2015-09-16 |
Summa Health System |
Vitamine c, vitamine k, un polyphénol et leurs combinaisons pour la cicatrisation des plaies
|
WO2014078427A1
(fr)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
Ester de d-alanine d'analogue de rp-nucléoside
|
EP2938624A1
(fr)
|
2012-11-14 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Ester de d-alanine d'analogue de sp-nucléoside
|
CN104955801B
(zh)
|
2012-11-30 |
2017-10-31 |
诺沃梅迪科斯有限公司 |
取代的二芳基磺酰胺及其用途
|
WO2014099941A1
(fr)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro-nucléosides pour le traitement du vhc
|
CA2895829A1
(fr)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Nouveaux derives de methysergide
|
WO2014137930A1
(fr)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Nucléosides de thiophosphate pour le traitement du vhc
|
EP2970358B1
(fr)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014165542A1
(fr)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoronucléosides pour le traitement du vhc
|
US20140377258A1
(en)
|
2013-05-30 |
2014-12-25 |
Infinity Pharmaceuticals, Inc. |
Treatment Of Cancers Using PI3 Kinase Isoform Modulators
|
EP3004130B1
(fr)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
|
EP3027636B1
(fr)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
Phosphoramidate de d-acides aminés pronucleotidiques dérivés de pyrimidine halogenée pour des maladies du foie
|
KR20160055170A
(ko)
|
2013-08-30 |
2016-05-17 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 아세트아미드 화합물 및 이의 사용 방법
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
EP3046924A1
(fr)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Inhibiteurs du virus de l'hépatite c
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MX2021012208A
(es)
|
2013-10-04 |
2023-01-19 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos y usos de los mismos.
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(fr)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
|
CN104587534A
(zh)
*
|
2013-10-31 |
2015-05-06 |
先健科技(深圳)有限公司 |
可吸收铁基合金支架
|
EP3063165A1
(fr)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
|
BR112016011949A8
(pt)
|
2013-11-27 |
2020-04-28 |
Idenix Pharmaceuticals Llc |
composto, composição farmacêutica, e, uso dos mesmos
|
WO2015081297A1
(fr)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
|
WO2015095419A1
(fr)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
Nucléosides 4'-or pour le traitement du vhc
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
CA2943075C
(fr)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Composes heterocycliques destines a etre utilises dans le traitement de troubles medies par pi3k-gamma
|
EP3119762B9
(fr)
|
2014-03-20 |
2021-10-20 |
Capella Therapeutics, Inc. |
Dérivés de benzimidazole en tant qu'inhibiteurs de la tyrosine kinase erbb pour le traitement du cancer
|
US10202398B2
(en)
|
2014-03-20 |
2019-02-12 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
US10106549B2
(en)
|
2014-04-09 |
2018-10-23 |
Siteone Therapeutics, Inc. |
10′,11′-modified saxitoxins useful for the treatment of pain
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
CN106456704A
(zh)
|
2014-04-16 |
2017-02-22 |
Veyx-药物有限公司 |
兽药组合物和其应用
|
WO2015168079A1
(fr)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
|
BR112016026560A2
(pt)
|
2014-05-12 |
2017-08-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
|
CA2947939A1
(fr)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Derives de nucleosides pour le traitement du cancer
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
CN110526912B
(zh)
|
2014-06-19 |
2023-02-14 |
武田药品工业株式会社 |
用于激酶抑制的杂芳基化合物
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
AR101476A1
(es)
|
2014-08-07 |
2016-12-21 |
Acerta Pharma Bv |
Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
|
KR20170066418A
(ko)
|
2014-09-12 |
2017-06-14 |
토비라 쎄라퓨틱스, 인크. |
섬유증의 치료를 위한 세니크리비록 병용 요법
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
LT3209647T
(lt)
|
2014-10-21 |
2020-09-25 |
Ariad Pharmaceuticals, Inc. |
Kristalinės 5-chlor-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il) piperidin-1-il]pirimidin-2,4-diamino formos
|
WO2016065264A1
(fr)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Dérivés de diterpénoïdes et leurs procédés d'utilisation
|
ES2805528T3
(es)
|
2014-12-23 |
2021-02-12 |
Sma Therapeutics Inc |
Inhibidores de 3,5-diaminopirazol quinasa
|
JP2018502889A
(ja)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
イソエルゴリン化合物およびその使用
|
EP3253753A4
(fr)
|
2015-01-20 |
2018-06-27 |
Xoc Pharmaceuticals, Inc |
Composés d'ergoline et leurs utilisations
|
WO2016189055A1
(fr)
|
2015-05-27 |
2016-12-01 |
Idenix Pharmaceuticals Llc |
Nucléotides pour le traitement du cancer
|
EP3302354B1
(fr)
|
2015-06-03 |
2023-10-04 |
i2o Therapeutics, Inc. |
Systèmes de mise en place d'implant
|
US20190015396A1
(en)
|
2015-06-23 |
2019-01-17 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
CN108371711A
(zh)
|
2015-08-17 |
2018-08-07 |
库拉肿瘤学公司 |
使用法尼基转移酶抑制剂治疗癌症患者的方法
|
JP2018534270A
(ja)
|
2015-09-30 |
2018-11-22 |
サイトワン セラピューティクス, インコーポレイテッド |
疼痛の治療のための11,13−修飾サキシトキシン
|
EP3368534B1
(fr)
|
2015-10-30 |
2021-01-27 |
Neurocrine Biosciences, Inc. |
Ditosylate de valbénazine et polymorphes associés
|
WO2017079566A1
(fr)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
HRP20220621T1
(hr)
|
2015-12-23 |
2022-06-24 |
Neurocrine Biosciences, Inc. |
Postupak sinteze za proizvodnju (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
|
RU2018127752A
(ru)
|
2015-12-31 |
2020-01-31 |
Конатус Фармасьютикалз Инк. |
Способы применения ингибиторов каспаз при лечении заболеваний печени
|
AU2017205170B2
(en)
|
2016-01-08 |
2021-06-24 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
ES2959267T3
(es)
|
2016-01-08 |
2024-02-22 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
|
PL3399978T3
(pl)
|
2016-01-08 |
2021-04-06 |
Celgene Corporation |
Związki antyproliferacyjne oraz ich kompozycje farmaceutyczne i zastosowania
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
CN108884019A
(zh)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
氘代氯胺酮衍生物
|
WO2017180794A1
(fr)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
MX2018013221A
(es)
|
2016-04-29 |
2019-06-24 |
Fgh Biotech Inc |
Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
AU2017268161B2
(en)
|
2016-05-16 |
2020-03-12 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
WO2017214269A1
(fr)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
CN110072861B
(zh)
|
2016-09-07 |
2022-11-11 |
Fgh生物科技公司 |
用于治疗疾病的二取代吡唑类化合物
|
US20190201409A1
(en)
|
2016-09-19 |
2019-07-04 |
Mei Pharma, Inc. |
Combination therapy
|
SG11201903786UA
(en)
|
2016-11-03 |
2019-05-30 |
Kura Oncology Inc |
Farnesyltransferase inhibitors for use in methods of treating cancer
|
WO2018089692A1
(fr)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Dérivés d'eckol, procédés de synthèse et utilisations associées
|
WO2018089427A1
(fr)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Sels de nitrite de 1,1-dimethylbiguanide, compositions pharmaceutiques et méthodes d'utilisation
|
JP7105774B2
(ja)
|
2016-12-01 |
2022-07-25 |
イグナイタ インコーポレイテッド |
がん治療のための方法
|
JP2020500875A
(ja)
|
2016-12-02 |
2020-01-16 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
|
CA3049034A1
(fr)
|
2017-01-03 |
2018-07-12 |
Intarcia Therapeutics, Inc. |
Methodes comprenant l'administration continue d'un agoniste du recepteur glp-1 et la co-adminstration d'un medicament
|
CA3051832A1
(fr)
|
2017-01-27 |
2018-08-02 |
Neurocrine Bioscienes, Inc. |
Methodes d'administration de certains inhibiteurs de vmat2
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
TWI738314B
(zh)
|
2017-02-21 |
2021-09-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
WO2018164996A1
(fr)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Posologie pour la valbénazine
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
EP3601291A1
(fr)
|
2017-03-29 |
2020-02-05 |
Siteone Therapeutics, Inc. |
Saxitoxines 11,13-modifiées destinées au traitement de la douleur
|
CN110914276A
(zh)
|
2017-03-29 |
2020-03-24 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
JP7237941B2
(ja)
|
2017-05-19 |
2023-03-13 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置用の融合複素環式芳香族アニリン化合物
|
MX2019013561A
(es)
|
2017-05-19 |
2022-02-09 |
Nflection Therapeutics Inc |
Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
|
BR112019025420A2
(pt)
|
2017-06-01 |
2020-06-16 |
Xoc Pharmaceuticals, Inc. |
Compostos policíclicos e usos destes
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
JP7325400B2
(ja)
|
2017-08-07 |
2023-08-14 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
|
EP3684333A2
(fr)
|
2017-09-21 |
2020-07-29 |
Neurocrine Biosciences, Inc. |
Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CN111836543A
(zh)
|
2017-10-10 |
2020-10-27 |
纽罗克里生物科学有限公司 |
施用某些vmat2抑制剂的方法
|
WO2019113269A1
(fr)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
JP7395480B2
(ja)
|
2018-01-10 |
2023-12-11 |
クラ セラピューティクス, エルエルシー |
フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
|
US20210052529A1
(en)
|
2018-01-10 |
2021-02-25 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
EP3814327A1
(fr)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
Dérivés d'acide (s)-3-(2-(4-(benzyl)-3-oxopipérazin-1-yl)acétamido)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque et composés apparentés utilisés en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
|
WO2020037022A1
(fr)
|
2018-08-15 |
2020-02-20 |
Neurocrine Biosciences, Inc. |
Procédés d'administration de certains inhibiteurs de vmat2
|
EP3860714B1
(fr)
|
2018-10-03 |
2023-09-06 |
Siteone Therapeutics, Inc. |
Saxitoxines 11,13-modifiées destinées au traitement de la douleur
|
AU2019372141A1
(en)
|
2018-11-01 |
2021-05-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
AU2019383310A1
(en)
|
2018-11-20 |
2021-06-10 |
H. Lee Moffitt Cancer Center & Research Institute |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
CN113473986A
(zh)
|
2018-11-20 |
2021-10-01 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
WO2020106307A1
(fr)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
|
JP7406264B2
(ja)
|
2018-11-20 |
2023-12-27 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのシアノアリール-アニリン化合物
|
WO2020132071A1
(fr)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Composés interagissant avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladie fibrotique
|
US20220071941A1
(en)
|
2018-12-21 |
2022-03-10 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
WO2020132700A1
(fr)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Procédés d'utilisation d'inhibiteurs de srebp en combinaison avec du niclosamide et des analogues de celui-ci
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
BR112021017710A2
(pt)
|
2019-03-07 |
2021-11-16 |
Conatus Pharmaceuticals Inc |
Composto, composição farmacêutica, método de tratamento
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
KR20210144778A
(ko)
|
2019-03-29 |
2021-11-30 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
|
WO2020205387A1
(fr)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Méthodes de traitement du cancer à l'aide d'inhibiteurs de la farnésyltransférase
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
WO2021007478A1
(fr)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Composés de sulfone et leurs compositions pharmaceutiques, et leurs applications thérapeutiques pour le traitement de maladies neurodégénératives
|
EP3996813A1
(fr)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Composés de phényle et compositions pharmaceutiques associées, et leurs applications thérapeutiques
|
KR20220039754A
(ko)
|
2019-07-26 |
2022-03-29 |
에스퍼비타 테라퓨틱스, 인크. |
질환의 예방 또는 치료에 유용한 작용화된 장쇄 탄화수소 모노- 및 다이-카복실산
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CA3154608A1
(fr)
|
2019-09-16 |
2021-03-25 |
Dice Alpha, Inc. |
Modulateurs d'il-17a et leurs utilisations
|
EP4034236A1
(fr)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Composés utiles pour le traitement des maladies du foie
|
WO2021067335A1
(fr)
|
2019-10-01 |
2021-04-08 |
Molecular Skin Therapeutics, Inc. |
Composés de benzoxazinone utilisés comme inhibiteurs doubles de klk5/7
|
EP4157271A1
(fr)
|
2020-05-29 |
2023-04-05 |
Boulder Bioscience LLC |
Procédés pour une thrombectomie endovasculaire améliorée à l'aide de 3,3'-diindolylméthane
|
EP4168414A1
(fr)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Thiénopyrimidines qui interagissent avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et d'une maladie fibreuse
|
IL300626A
(en)
|
2020-08-14 |
2023-04-01 |
Siteone Therapeutics Inc |
Ketone-free inhibitors of NAV1.7 for the treatment of pain
|
WO2022165000A1
(fr)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Méthodes pour le traitement d'une maladie fibrotique
|
WO2022164997A1
(fr)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Méthodes pour le traitement d'une maladie fibrotique
|
WO2022189856A1
(fr)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Composés utiles pour le traitement des maladies du foie
|
WO2022192545A1
(fr)
|
2021-03-10 |
2022-09-15 |
Dice Molecules Sv, Inc. |
Inhibiteurs de l'intégrine alpha v bêta 6 et alpha v bêta 1 et leurs utilisations
|
EP4326721A1
(fr)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
|
WO2022251533A1
(fr)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Hétéroaryl-diamides activateurs d'ire1/xbp1s
|
TW202327590A
(zh)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
大環化合物及組合物以及其製備及使用方法
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023192817A1
(fr)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibiteurs de la famille myst des lysine acétyltransférases
|
US20230348909A1
(en)
|
2022-03-30 |
2023-11-02 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
TW202406901A
(zh)
|
2022-04-14 |
2024-02-16 |
美商必治妥美雅史谷比公司 |
新穎gspt1化合物以及新穎化合物之使用方法
|
WO2023201348A1
(fr)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Procédés de prédiction de la réactivité d'un lymphome à un médicament et méthodes de traitement du lymphome
|
WO2023211990A1
(fr)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur
|
WO2023215781A1
(fr)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Méthode de traitement de la dystrophie musculaire de duchenne
|
WO2024054832A1
(fr)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
COMPOSÉS DE DÉGRADATION CK1α ET DOUBLE CK1α/GSPT1
|
WO2024073473A1
(fr)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprenant du 3,3'-diindolylméthane pour traiter une blessure fermée à la tête non hémorragique
|
WO2024086246A2
(fr)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3-djpyrimidin-4-ones substituées en position 2 pour le traitement des plaies
|
WO2024092043A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés de pyridine contenant un spirocycle
|
WO2024092037A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés de pyridone contenant un spirocycle
|
WO2024092040A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés hétéroaryle bicycliques contenant un spirocycle
|